Catch up on company announcements, industry insights, partnerships, and milestones. Here’s where we share our progress, and where we’re headed next.
Press Release
Beacon Biosignals Completes Strategic Transaction to Acquire CleveMed
Beacon Biosignals
Apr 21, 2025
Press Release
Beacon Biosignals Reports Novel Sleep EEG Results from Multiple Industry Collaborations at the American Epilepsy Society Annual Meeting
Beacon Biosignals
Dec 13, 2024
Press Release
FDA Authorizes Beacon’s Dreem 3S as First Sleep Wearable with Predetermined Change Control Plan, Paving the Way for Continuous Algorithm Enhancements in Sleep Monitoring
Beacon Biosignals
Dec 3, 2024
Press Release
Beacon Launches HEADFIRST Clinical Trial to Study Sleep EEG in Pediatric Developmental Disorders, Partners with LGS Foundation
Beacon Biosignals
Sep 18, 2024
Press Release
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
Beacon Biosignals
Jul 24, 2024
Press Release
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions
Beacon Biosignals
May 13, 2024
Press Release
Beacon Biosignals and Takeda Launch Strategic Collaboration to Advance Neurobiomarkers and Endpoints for Sleep Disorders
Beacon Biosignals
Apr 30, 2024
Press Release
Beacon Biosignals Expands Sleep Analysis Capabilities with FDA Clearance of SleepStageML
Beacon Biosignals
Mar 27, 2024
Press Release
Beacon Biosignals welcomes David Matthews, PhD, as Chief Business Officer
Beacon Biosignals
Feb 1, 2024